Rimegepant
- Generic Name
- Rimegepant
- Brand Names
- Nurtec, Vydura
- Drug Type
- Small Molecule
- Chemical Formula
- C28H28F2N6O3
- CAS Number
- 1289023-67-1
- Unique Ingredient Identifier
- 997WVV895X
- Background
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its re...
- Indication
Rimegepant is indicated for the acute treatment of migraine with or without aura in adults. Rimegepant is also indicated for the prevention of episodic migraine in adults.
- Associated Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 496
- Registration Number
- NCT05399485
- Locations
- đ¯đĩ
Higashi Sapporo Neurology and Neurosurgery Clinic, Sapporo-shi, Hokkaido, Japan
đ¯đĩShinagawa Strings Clinic, Minato-ku, Tokyo, Japan
đ¯đĩFukuuchi Pain Clinic, Shinjuku-ku, Tokyo, Japan
Cluster Headache Treatment With Rimegepant
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT05264714
- Locations
- đēđ¸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 126
- Registration Number
- NCT05262517
- Locations
- đēđ¸
The Medici Medical Research, LLC, Hollywood, Florida, United States
đēđ¸The Medici Medical Research, Hollywood, Florida, United States
đēđ¸Clinvest Research, LLC, Springfield, Missouri, United States
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 255
- Registration Number
- NCT05207865
- Locations
- đēđ¸
Boston Clinical Trials, Boston, Massachusetts, United States
đēđ¸Phoenix Medical Research, LLC, Miami, Florida, United States
đēđ¸Velocity Clinical Research, Cincinnati, Ohio, United States
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8082
- Registration Number
- NCT05198245
- Locations
- đēđ¸
Research Triangle Institute d/b/a RTI Health Solutions, Research Triangle Park, North Carolina, United States
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT05156398
- Locations
- đ¯đĩ
Tominaga Clinic, Naniwa-ku, Osaka-shi, Osaka, Japan
đ¯đĩSaitama Neuropsychiatric Institute, Chuo-ku Saitama-shi, Saitama, Japan
đ¯đĩTokyo Headache Clinic, Shibuya-ku, Tokyo, Japan
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 580
- Registration Number
- NCT05127486
- Locations
- đēđ¸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
đēđ¸Gilbert Neurology, Gilbert, Arizona, United States
đēđ¸California Medical Clinic for Headache and The Los Angeles Headache Center (Research Facility), Los Angeles, California, United States
Rimegepant in Moderate Plaque-type Psoriasis
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 41
- Registration Number
- NCT04629950
- Locations
- đēđ¸
Weill Cornell Medicine, New York, New York, United States
đēđ¸Sadick Dermatology, New York, New York, United States
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1648
- Registration Number
- NCT04574362
- Locations
- đ¨đŗ
1st Hospital of Jilin University, Changchun, Jilin, China
đ¨đŗShandong Provincial Qianfoshan Hospital, Jinan, Shandong, China
đ°đˇKangdong Sacred Heart Hospital, Seoul, Korea, Republic of
Trial for Treatment Refractory Trigeminal Neuralgia
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT03941834
- Locations
- đēđ¸
Center for Neurohealth DBA Kaizen Brain Center, La Jolla, California, United States
đēđ¸Imaging Clinic at Stanford Neuroscience Health Center, Palo Alto, California, United States
đēđ¸Stanford Neuroscience Health Center- SNHC Pharmacy, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.